APHINITY | AACR Cancer Research | Frontier Science Scotland

TITLE OF PUBLICATION

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial

Authors

Richard D.Gelber; Xin V.Wang; Bernard F.Cole; David Cameron; Fatima Cardoso; Vivianne Tjan-Heijnen; Ian Krop; Sherene Loi; Roberto Salgado; Astrid Kiermaier; Elizabeth Frank; Debora Fumagalli; Carmela Caballero; Evandro de Azambuja; Marion Procter; Emma Clark; Eleonora Restuccia; Sarah Heeson; Jose Bines; Sibylle Loiblt; Martine Piccart-Gebhart on behalf of the APHINITY Steering Committee and Investigators

PUBLICATION REFERENCES

CANCER RESEARCH | Volume 82 | Issue 4 | Page(s) Supplement | Publication Year 2022

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

Cardiac Safety in the APHINITY trial

Jan 30, 2023

ESMO Open has published an article confirming the cardiac safety of adjuvant anti-HER2 treatment with pertuzumab and trastuzumab.

NeoALTTO: European Journal of Cancer (EJC)

Jan 16, 2023

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

Overall survival in the OlympiA trial

Dec 1, 2022

OlympiA demonstrates statistically significant improvement in overall survival with adjuvant olaparib compared with placebo

APHINITY | Annals of Oncology

Sep 1, 2022

Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up

OlympiA | ESMO Virtual Plenary Abstract | Annals of Oncology

May 9, 2022

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

APHINITY | Journal of the National Cancer Institute (JNCI)

May 5, 2022

Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy

APHINITY | European Journal of Cancer (EJC)

Mar 18, 2022

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

The ALTTO Trial: Updated Results from the international phase III ALTTO trial (BIG2-06/Alliance N063D)

May 1, 2021

Presentation of the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial as shown at the 2017 annual meeting of the American Society of Clinical Oncology and published in the European Journal of Cancer in 2021.

The APHINITY Trial: Results of the Interim Overall Survival Analysis at 6 years’ follow-up